Life Science Transactions Strategies (LSTS) helps life science innovators to advance the development and commercialization of new drugs and vaccines by negotiating strategic transactions, such as R&D, collaboration, licensing, and funding agreements. LSTS is the solo legal practice of Gillian M Fenton.
Ms. Fenton provides legal support to business development (BD) professionals engaged in a range of intellectual property (IP) driven transactions, including asset acquisitions, technology transfers, material transfer agreements, technology evaluation and option agreements, sponsored research agreements, consulting agreements, clinical trial agreements, funding agreements, licenses (in-bound, out-bound and cross-licensing arrangements), collaboration and joint development agreements, clinical trial agreements, and asset sales/dispositions. Ms. Fenton has structured agreements covering patent rights, trademarks, trade secrets, know-how, unique biological materials, and data. She has negotiated agreements for a wide range of life science technologies: from vaccines, antibody-based therapeutics, biologics, and point of care medical devices, to novel drug development platforms and manufacturing technologies. She is also familiar with agreements at the innovator-vendor interface such as R&D services agreements and supply agreements.
Ms. Fenton supports life science businesses in all aspects and stages of U.S. government contracting, including contracts based on the Federal Acquisition Regulation (FAR) and Other Transactional Authority (OTA), from proposal through performance to contract closeout. Similarly, Ms. Fenton provides legal support to businesses engaging in other types of agreements with U.S. government entities, including Cooperative Research and Development Agreements (CRADAs), clinical trial agreements, and nonexclusive and exclusive licenses of government owned IP rights. Her experience spans across the entire collaborative life cycle from initial application for license rights to negotiation, compliance, alliance management, and resolution of royalty disputes. She has supported contracts with a range of agencies and national laboratories including BARDA, NIH, DARPA, CARB-X, NIIMBL and the Lawrence Livermore National Laboratories. She is also familiar with the contracting requirements of major nongovernmental R&D funders such as the Bill & Melinda Gates Foundation, CEPI, and the Wellcome Trust.
An understanding of the Bayh-Dole Act and its implications for life science businesses developing products and services arising from patent rights subject to the Act is critical for successfully navigating the risks and opportunities of commercialization. Ms. Fenton has experience in advising clients on how the Act works and how to comply with its requirements. She has successfully applied for and received waivers of the Act’s domestic manufacturing requirement, which impacts innovators’ ability to utilize global resources to support global markets for vaccines and other biologic products.
As a former VP level Chief IP Counsel, Ms. Fenton provides advice and support to in-house IP counsels responsible for developing and implementing IP strategy. She has published extensively on the three dimensions of IP strategy (asset management, risk mitigation, and value extraction) and can coach in-house counsel in communicating resource needs and identifying value metrics. However, LSTS does not accept engagements for patent preparation and prosecution.
LSTS was founded by Gillian M. Fenton, Esq. CLP, whose law practice centers on life science transactions, collaborations, business- and corporate-development. Ms. Fenton has over 30 years of experience in licensing and other types of agreements that utilize intellectual property (IP) assets to propel the growth and development of businesses in life sciences industries (biotechnology and pharmaceuticals). Ms. Fenton has provided business development (BD) and alliance management (AM) legal support for transactions involving products and product candidates ranging from discovery stage through commercial launch. She also has experience in negotiating, managing, and closing out U.S. government contracts supporting research and development of new technologies. A former VP level Chief IP Counsel, she also has expertise in all aspects of IP strategy including asset management, risk management, and value extraction.
Certified Licensing Professional (CLP)
IAM 300: World's Leading IP Strategists
Practitioner in Residence, Center for Intellectual Property x Innovation Policy
Recipient of the Frank Barnes Award, Licensing Executive Society USA & Canada
Admitted to practice law in Massachusetts, Maryland, and the District of Columbia. Registered U.S. patent attorney.
Suffolk University Law School - J.D. cum laude
Trinity College - B.Sc. Biochemistry
Through LSTS, Ms. Fenton seeks to add value to life science enterprises through effective, pragmatic, collaborative legal advice and negotiation services. Far more can be achieved from a win-win mindset than by approaching potential partners with a zero-sum attitude. Ms. Fenton also brings an entrepreneurial, creative, can-do mindset to difficult legal and business issues. Clarity and fairness are the bedrock of productive, long-lasting business relationships. Ms. Fenton understands that these qualities must be reflected in the legal agreements that are the foundation of such relationships.
Content in this website, including downloads, is provided for informational and educational purposes only, and does not constitute legal advice. No attorney-client relationship is created unless and until an engagement letter is signed for LSTS services.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.